Frailty (the gradual loss of physical reserve that leaves older adults vulnerable to falls, illness, and loss of independence) is one of the most pressing challenges in aging medicine. At its core, frailty involves declining muscle mass and function, a condition closely linked to impaired energy production inside muscle cells. Researchers have increasingly focused on mitochondria, the cellular structures that generate energy, as a key driver of this decline.
Urolithin A is a compound produced when gut bacteria metabolize ellagitannins found in foods like pomegranates, walnuts, and certain berries. It has attracted scientific attention because it activates mitophagy: the cellular process by which damaged mitochondria are identified and recycled, allowing healthier ones to take their place. Several clinical trials have now tested whether supplementing with urolithin A can meaningfully support muscle health in aging adults, offering a potential nutritional approach to one dimension of frailty.
Key Takeaways
- Urolithin A activates mitophagy, the cellular recycling of damaged mitochondria, which declines with age and contributes to the muscle loss underlying frailty.
- A randomized clinical trial in older adults (65 to 90) reported improvements in muscle endurance and some plasma biomarkers after four months, but these were secondary endpoints; there was no significant improvement over placebo in six-minute walk distance or maximal muscle ATP production [1].
- Many older adults cannot efficiently produce urolithin A from food because their gut microbiome lacks the necessary bacteria, making supplemental forms relevant to research [2].
- No trial has yet measured urolithin A against clinical frailty endpoints like falls, hospitalizations, or formal frailty scores: the evidence base is mechanistic and performance-focused, not outcome-focused.
- Urolithin A appears safe in the doses studied, but it is a supplement, not a treatment, and should not replace medical management of sarcopenia or frailty.
Understanding Frailty and Its Cellular Roots
Frailty is not simply being ‘old and weak.’ Clinically, it describes a state of reduced physiological reserve in which even minor stressors (an infection, a missed meal, a fall) can trigger a cascade of serious consequences. Muscle loss is central to this picture. Sarcopenia, the age-related decline in skeletal muscle mass and strength, affects a substantial proportion of older adults and is a major contributor to frailty, disability, and loss of independence [3].
What drives sarcopenia at the cellular level? One well-studied factor is mitochondrial dysfunction. Aging muscle accumulates damaged, poorly functioning mitochondria that generate less energy and more oxidative stress. When the normal housekeeping process of mitophagy, the selective clearance of these dysfunctional mitochondria, slows down, muscle cells become progressively less efficient. Nutritional factors, including inadequate intake of compounds that support mitochondrial turnover, may accelerate this decline [4].
The gut microbiome also plays a role. The bacteria responsible for converting dietary ellagitannins into urolithin A are not evenly distributed across the population, and their abundance tends to decline with age. This means that older adults may produce less urolithin A from food, since metabotype changes with age, health status and obesity, though this varies widely between people [12][13][2]. Changes in gut microbial ecology associated with aging have also been linked to sarcopenia through inflammatory and metabolic pathways [5].
How Urolithin A Activates Mitophagy
Mitophagy is a form of selective autophagy: the cellular ‘self-eating’ process by which damaged components are tagged, engulfed, and broken down for recycling. In healthy muscle, mitophagy continuously removes worn-out mitochondria, making room for new, functional ones. When this process is impaired, as commonly occurs with aging, dysfunctional mitochondria accumulate and muscle performance suffers.
Research note: A 2026 review notes there are currently no approved therapies for sarcopenia; urolithin A is listed only among candidate approaches that target mitochondrial function [17].
Urolithin A was identified as a mitophagy activator through systematic screening of natural compounds. Unlike some interventions that broadly suppress autophagy or act through multiple simultaneous pathways, urolithin A is proposed to stimulate mitophagy, but lab work also points to other targets such as the aryl hydrocarbon receptor and Nrf2, and in one mouse liver study its protection persisted with mitophagy blocked, so the mechanism is not settled [14][15][16]. The first human trial reported a favourable safety profile as its primary outcome, and changes in plasma acylcarnitines and muscle mitochondrial gene expression as secondary outcomes, which are biomarker signals rather than proof of benefit [6].
Mitophagy is one proposed mechanism, though not the only one reported, and it is one reason urolithin A has been studied in aging and muscle health: restoring mitophagy is a plausible strategy [16][14] for supporting the muscle quality that frailty erodes.
Clinical Evidence in Older Adults
The most directly relevant trial for frailty was a randomized clinical trial published in JAMA Network Open in 2022, enrolling older adults aged 65 to 90 who were not regularly exercising. Participants received either urolithin A supplementation or placebo for four months. The trial did not significantly improve its main measures, six-minute walk distance and maximal muscle ATP production, versus placebo. A secondary endpoint, muscle endurance (contractions until fatigue), did improve at 2 months, but with very large standard deviations [1]. Plasma biomarker analyses showed lower levels of several acylcarnitines, ceramides and C-reactive protein with urolithin A than with placebo [1].
A complementary trial published in Cell Reports Medicine the same year enrolled a middle-aged cohort and found that urolithin A supplementation over four months missed its primary endpoint, with some secondary measures such as hamstring strength and C-reactive protein favouring urolithin A [7]. While this cohort was younger than a typical frailty population, the mitochondrial biomarker improvements are mechanistically relevant to what occurs in aging muscle.
These findings are modest and specific: improvements in endurance and biomarkers, not reversal of frailty itself. Neither trial was designed to measure clinical frailty outcomes such as falls, hospitalizations, or functional independence, which would require much larger and longer studies.
Two limits matter for older readers: walk distance improved in both the placebo and urolithin A groups, which the authors think may reflect higher activity from simply taking part, and the trial enrolled only White participants from the Seattle area. The funder, Amazentis SA, had a role in study design, data analysis and the decision to submit for publication [1].
Beyond Muscle: Joint and Broader Cellular Health
Frailty in older adults is rarely confined to muscle loss alone. Osteoarthritis, chronic pain, and reduced mobility compound the picture. A 2022 study in Aging Cell examined urolithin A in the context of osteoarthritis and reported that it reduced cartilage degeneration markers and alleviated pain in relevant models, with mitophagy activation proposed as the underlying mechanism [8]. While this is not a direct frailty trial, joint health and pain are significant contributors to the activity limitation that accelerates frailty progression.
More broadly, a systematic review of randomized controlled trials examining nutraceuticals and mitochondrial health in aging found that interventions targeting mitochondrial function showed mixed but occasionally positive effects on markers of cellular aging [9]. Urolithin A was among the compounds reviewed, reinforcing that its effects fit within a broader landscape of nutritional strategies targeting the biology of aging.
Individual Variability and the Gut Microbiome
A practical complication for using urolithin A from food sources is that the capacity to produce it varies widely between individuals, depending on gut microbiome composition. Studies have shown that the microbial metabolism of ellagitannins to produce urolithin A is not universal: a meaningful fraction of people lack the necessary gut bacteria to convert dietary precursors efficiently [2]. Age-related changes in gut microbial ecology, including reduced diversity and altered bacterial populations, may further impair this conversion in older adults [5].
This variability is part of the rationale for studying purified urolithin A supplements rather than food-based interventions: it removes the microbiome bottleneck and allows for more consistent dosing. Clinical trials to date have used standardized supplemental forms, so results from food-based approaches may differ substantially from person to person.
Where the Evidence Is Still Developing
Current trials, while promising in their mechanistic consistency, have notable limitations for frailty specifically. The largest trials have run for four months: long enough to detect biomarker and performance changes, but short relative to the timeline of frailty progression. None have used standard frailty assessment tools (such as Fried criteria or the Clinical Frailty Scale) as primary endpoints, and none have followed participants long enough to assess outcomes like falls or hospitalization.
Research in highly trained runners found no significant improvement in a 3,000 m time trial, and the authors concluded urolithin A did not further enhance performance [10], [10] but translating findings from athletes to frail older adults requires caution: the biology of overtraining and aging muscle, while overlapping, are distinct. Autophagy-supporting compounds from other natural sources, such as those found in Castanea crenata flower extract, have shown muscle-protective effects in aging models [11], pointing to a broader class of mitophagy-activating interventions worth studying, though urolithin A remains the most clinically tested in humans.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The clinical evidence for urolithin A and muscle health is promising but early: trials to date have been small, short, and have not measured clinical frailty outcomes such as falls or loss of independence. Urolithin A is a dietary supplement, not a treatment for frailty or sarcopenia, and should not replace medical care, exercise, or adequate protein intake. Older adults with chronic illnesses, kidney disease, or who take multiple medications should consult a physician before adding any new supplement.
Frequently Asked Questions
What is urolithin A and where does it come from?
Urolithin A is a compound produced by gut bacteria when they metabolize ellagitannins: polyphenols found in pomegranates, walnuts, and certain berries. Because production depends on specific gut microbes, many people cannot generate meaningful amounts from food alone [2]. Supplemental forms bypass this variability.
How does urolithin A relate to muscle aging and frailty?
Age-related muscle loss (sarcopenia) involves accumulation of dysfunctional mitochondria in muscle cells. Urolithin A activates mitophagy, the process that clears these damaged mitochondria, which tends to slow down with aging. By restoring mitophagy, urolithin A may support muscle quality at the cellular level [6]. Sarcopenia is a central contributor to frailty in older adults [3].
Has urolithin A been tested specifically in older adults?
Yes. A randomized trial in older adults did not significantly improve its main measures, six-minute walk distance and maximal muscle ATP production, but a secondary endpoint, muscle endurance (contractions to fatigue in a hand muscle and a leg muscle), improved at 2 months with very large standard deviations [1]. This is the most directly relevant trial for a frailty-adjacent population.
Does urolithin A reduce frailty itself?
Not as directly measured. No published trial has used formal frailty assessment tools as primary endpoints or tracked frailty-related outcomes like falls or functional decline over time. The existing evidence covers muscle endurance, exercise performance, and mitochondrial biomarkers: meaningful signals, but not the same as demonstrated reductions in clinical frailty.
Is urolithin A safe for older adults to take?
Early safety data from dose-escalation studies found urolithin A was well tolerated across multiple dose levels in adults, with no serious adverse events attributed to the supplement [6]. However, as with any supplement, older adults, especially those with chronic conditions or taking multiple medications, should discuss it with their doctor before starting.
Can diet alone provide enough urolithin A to support muscle health?
Probably not for most older adults. The gut bacteria needed to convert ellagitannins to urolithin A are not universally present, and their abundance may decline with age-related changes in gut microbial ecology [5]. Clinical trials showing muscle benefits used standardized supplement forms, not dietary interventions, so food-based strategies cannot be assumed to produce equivalent results.
References
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Selma MV et al. The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism. Food & function (2016). PMID 26597167
- Dao T et al. Sarcopenia and Muscle Aging: A Brief Overview. Endocrinology and metabolism (Seoul, Korea) (2020). PMID 33397034
- Guralnik JM et al. Nutritional Mediators of Cellular Decline and Mitochondrial Dysfunction in Older Adults. Geriatrics (Basel, Switzerland) (2021). PMID 33917371
- Wang M et al. Age-related sarcopenia and altered gut microbiota: A systematic review. Microbial pathogenesis (2024). PMID 39142365
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- D'Amico D et al. Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis. Aging cell (2022). PMID 35778837
- Lippi L et al. Impact of nutraceuticals and dietary supplements on mitochondria modifications in healthy aging: a systematic review of randomized controlled trials. Aging clinical and experimental research (2022). PMID 35920994
- Whitfield J et al. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. Sports medicine (Auckland, N.Z.) (2025). PMID 40839339
- Park SH et al. A Natural Autophagy Activator Castanea crenata Flower Alleviates Skeletal Muscle Ageing. Journal of cachexia, sarcopenia and muscle (2025). PMID 39873130
- Silvana Alfei et al. Oxidative Stress, Antioxidant Capabilities, and Bioavailability: Ellagic Acid or Urolithins?. Antioxidants (2020). PMID 32759749
- Cortés-MartÃn A et al. The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging. Food & function (2018). PMID 30004553
- Shen PX et al. Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor. EBioMedicine (2021). PMID 33530002
- Muku GE et al. Urolithin A Is a Dietary Microbiota-Derived Human Aryl Hydrocarbon Receptor Antagonist. Metabolites (2018). PMID 30501068
- Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
- Ancel S et al. Strengthening muscle for healthy ageing: innovative treatments for sarcopenia. Nature reviews. Drug discovery (2026). PMID 42706321
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.